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 Abstract 
 
 HIV-1 predominantly uses CD4 and the chemokine receptor, CCR5 to gain entry 
into host cells.  Different strains vary in ability to infect cells with low receptor 
concentrations.  The MQP’s purpose was to analyze molecular clones of an HIV variant 
that could infect T-cells expressing low amounts of CCR5.  Such variants may confer a 
broader tropism for immune cells.  Envelope clones were tested for their ability to fuse 
with cells expressing different concentrations of CD4 and CCR5.  Variant envelope 
clones that were more fusiogenic for cells with low CCR5 or CD4 were identified.  
Amino acid substitutions in V2 and a region that binds CD4 were identified as potential 
determinants of the variant phenotype. 
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BACKGROUND 
 
HIV Introduction 
Virus Overview 
 
 The Human Immunodeficiency Virus (HIV) is in the genus of lentiviruses that is 
a part of the family Retroviridae.  Characteristics presented by lentiviruses include long 
and variable incubation periods, persistent viral replication, neurological complications 
and destruction to particular types of hematologic or immunologic cells (Desrosiers and 
Letvin, 1987).  There is extensive genetic and antigenic variability exhibited and a strong 
tropism for macrophages (Coffin, et al, 1997).  Furthermore lentiviruses have a common 
morphology and morphogenesis along with specific regulatory genes not found in other 
groups of viruses in the Retroviridae family (Coffin, et al, 1997). 
 There are two different HIV virus groups, HIV-1 and HIV-2, for the only known 
lentiviruses affecting humans (Knipe and Howley, 2001).  HIV-1 is more predominant 
than HIV-2 to which most cases are only found in Western Africa (Coffin, et al, 1997).  
HIV-1 is closely related to SIVcpz in chimpanzees, while HIV-2 is closely related to 
SIVsmm in sooty mangebey monkeys.  It is thought that both HIV-1 and HIV-2 emerged 
via zoonotic transmission to man (Knipe and Howley, 2001).  HIV-1 has different types 
separated into three distinct groups.  The first group is group M or main group, the 
second group is the O or outlier, and the third group is the recently discovered N group 
found to infect Cameroonians (Knipe and Howley, 2001).  The groups are further 
separated into genetic subtypes.  The M type virus has can be separated into at least 8 
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different subtypes labeled A-J (Knipe and Howley, 2001).  Figure 1 below shows the 
global prevalence of HIV-1. 
 
Figure 1: HIV-1 Subtypes and Their Worldwide Distribution as of 1998.  The larger 
circles indicate the predominant subtype in the areas they are located (Knipe and 
Howley, 2001).      
 
Host and viral factors contribute to the pathogenicity of HIV-1 and HIV-2 diseases 
(Cohen et al, 1997).  The factors include the tropism of the virus, co-receptor use, viral 
escape from the immune response, and the virus’s overall ‘fitness’ or effectiveness.  The 
virus goes through 3 major stages of disease progression dictated by the CD4+ T-cell 
counts in an infected individual (Fauci et al, 1996) (Figure 2).  The three stages are acute, 
asymptomatic, and symptomatic infection.    
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 Figure 2: Typical Course of HIV Infection in Humans (Fauci et al, 1996). 
 
Viral Composition 
 
 The HIV-1 genome includes all of the typical retroviral structural genes including 
gag, pol, and env (Wiley, 2001).  The HIV genome consists of RNA and is more complex 
than other retroviruses with at least 6 more genes (Wiley, 2001) in its genome, including 
tat, rev, nef, vif, vpr, vpu (Wiley, 2001).  Table 1 shows the names of the genes and the 
function of the proteins they encode. 
 
Gene Name Proteins Encoded 
Group-specific Antigen (gag) Structural Protein; Precursor for the Matrix 
(MA), Capsid (CA), Nucleocapsid (NC), 
and p6 proteins. 
Polymerase (pol) Structural Protein; Protease (PR), Reverse 
Transcriptase (RT), and Integrase (IN). 
Envelope (env) Structural Protein; Envelope glycoproteins 
Trans-activator of viral transcription (tat) Regulatory Protein; Enhances transcription.
Regulator of Viral Protein Expression (rev) Regulatory Protein; Regulates RNA 
splicing. 
Negative Factor (nef) Accessory Protein; Enhances viral 
replication.  Down modulation and 
degradation of CD4 and MHC class I.  
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Virus Infectivity Factor (vif) Accessory Protein; Crucial for infectious 
virons specific to cell type. 
Viral Protein R (vpr) Accessory Protein; Stimulates viral gene 
expression.  Important for infection of non-
dividing cells. 
Viral protein U (vpu) Accessory Protein; Enhances virus release 
and degrades CD4. 
 
Table 1: HIV Genes and a Brief Description of the Encoded Protein’s Function 
(Wiley, 2001; Knipe and Howley, 2001). 
 
Additionally to the genes found within the 9.7 kb (Knipe and Howley, 2001) HIV 
genome there are two long terminal repeats (LTR).  The LTR regions are divided into 3 
domains U3, U5, and a central region, R (Wiley, 2001).  The U3 domain is about 450 bp 
long and the U5 domain is around 80 bp which are untranslated regions (Wiley, 2001).  
The R region or central repeated region is approximately 100 bp long and it contains 
sequences vital to the control of transcription and encodes a binding site for the Tat 
protein (Wiley, 2001). 
Structural Proteins 
 The structural proteins found in the HIV genome are common to all retroviruses.  
The structural proteins are synthesized from polyprotein precursors (Knipe and Howley, 
2001).  The Gag precursor (Pr55Gag) is 55 kDa in size and is cleaved into 4 different 
proteins (Knipe and Howley, 2001) the matrix (MA, p17), capsid (CA, p24), 
nucleocapsid (NC, p7), and p6 proteins.  The matrix protein is myristoylated and 
aggregates under the cell membrane.  Its role is involved with the incorporation of the 
Env polyprotein via interactions with the long cytoplasmic tail of gp41 (Wiley, 2001).  
The capsid protein forms the central core of the HIV virus particle (Wiley, 2001).  The 
CA protein also contains a region to which there is a dimerization domain; this allows for 
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the CA-CA interactions to form the core of the virus (Wiley, 2001).  The NC protein’s 
major role is to encapsulate the viral genomic RNA and deliver it to the assembling viron 
(Wiley, 2001).  At the C-terminus of the Gag polyprotein there is a proline rich, 6 kDa 
protein p6.  This protein has a role in the late stages of viral release and it has been shown 
to recruit cellular proteins required for virus budding from the host cell (Freed, 2002). 
The second structural polyprotein is Pol.  It is translated as a part of a Gag-Pol 
product from a ribosomal frameshift during Gag translation which creates the p160 Gag-
precursor (Wiley, 2001).  The precursor is cleaved into three separate proteins: viral 
protease (PR, p10), reverse transcriptase (RT, p66), and Integrase (IN, p32) (Knipe and 
Howley, 2001).  The PR protein is essential for viron maturation events following the 
budding from the host cell (Wiley, 2001).  The protein is involved in cleaving the poly 
proteins from both the Gag and Gag-Pol polyproteins (Wiley, 2001).  Reverse 
transcriptase (RT) is an enzyme that is a heterodimer as p51 and p66, its activity is 
involved with the synthesis of double stranded DNA from a single stranded RNA 
template (Wiley, 2001).  The IN protein catalyzes a series of reactions that take place in 
the culmination of the integration of the viral DNA into the host genome (Wiley, 2001). 
 The third structural protein is Env.  The Env protein is a glycoprotein that is a 
precursor (gp160) to two proteins, gp120 and gp41.  The gp120 or surface subunit of Env 
is highly glycosylated and offers protection against host antibodies (Losman et al., 2001).  
The protein is also the first contact with target host cell receptors (Wiley, 2001).  The 
transmembrane subunit of Env or gp41 has a hydrophobic domain that confers fusion of 
viral and host membranes (Wiley, 2001). 
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Regulatory Proteins 
 
 HIV has two regulatory proteins in its genome.  The first one is transcribed from 
the tat or Transactivator of viral transcription.  This gene encodes a protein of about 14 
kDa in size (Knipe and Howley, 2001).  The tat gene contains 2 exons and in vivo either a 
one exon or two exon protein is found (Rhim and Rice, 1994).  The functional domain of 
the protein is located in the first exon and alone can enhance transcription activity by 
binding the transactivating response (TAR) element on newly initiated HIV mRNA 
molecules (Wiley, 2001). 
 The second regulatory protein is encoded by the rev gene to form the regulator of 
viral protein expression.  The protein is 116 amino acids long and 19 kDa in size (Wiley, 
2001).  This protein’s function is to regulate the transport of unspliced viral mRNAs by 
binding to specific RNA sequences and structures (Wiley, 2001). 
 
Accessory Proteins 
 
 The HIV genome also encodes four accessory proteins.  The proteins are unique 
to lentiviruses and are given the name as accessory due to the fact that they are not 
absolutely necessary in viral replication at least in vitro (Wiley, 2001).  However they 
perform important roles in the virus’s functions in vivo (Wiley, 2001).  The first protein is 
encoded by the nef gene (Aiken and Trono, 1995).  The 27 kDa nef protein is involved 
with CD4 and MHC class I down regulation and modulation of cellular activation 
pathways (Chowers et al., 1994). 
 The second accessory protein is encoded by the vif gene and makes a 23 kDa 
(Knipe and Howley, 2001) protein called Virus Infectivity Factor.  The protein is 
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involved with the stage of virus assembly and is important for the production of 
infectious virus particles (Gabuzda et al., 1994) by inducing degradation of an antiviral 
cellular protein, APOBEC3A (Rose et al, 2004). 
 The Vpr protein is encoded by the vpr gene to produce Viral Protein R. Vpr acts 
to increase virus expression and is involved with functions during early post-entry stages 
of the replication cycle of HIV (Bukrinsky and Adzhubei, 1999).  In SIV and HIV-2 the 
two vpr functions are separated onto two proteins called vpr and vpx (Fletcher et al, 
1996). 
 The gene vpu encodes a 16 kDa protein called viral protein U or p16.  This 
protein is an integral membrane protein that has major roles in the degradation of CD4 
within the ER and stimulating the release of virus (Willey et al., 1992).  Figure 3 shows 
the genomic map of HIV and shows the proteins encoded by it.  
Viral Cell Entry 
Structure of Virion Surface 
 
 HIV virus particles attach to cell receptors via the glycoprotein spikes (Clapham 
and McKnight, 2002) on the surface of the virus.  The envelope spikes are composed of 
two proteins gp120 and gp41.  The proteins are also referred to as surface (SU) envelope 
protein (gp120) and transmembrane (TM) envelope protein (gp41).  The envelope 
proteins are made from a gp160 precursor molecule as seen in Figure 3.  The precursor 
molecule gp160 is cleaved in the Golgi apparatus by a cellular protease (Clapham and 
McKnight, 2002) to make the two glycoproteins that form the envelope spike.  Each 
spike is made up of 3 gp120 and 3 gp41 proteins held together as a trimer (Clapham and 
McKnight, 2002). 
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 Figure 3: Map of the HIV Genome and the Proteins Encoded by Each Gene.  The 
sizes of the products are listed in kilodaltons (Knipe and Holey, 2001). 
 
 
The gp120 protein has 5 variable loops in its structure (V1-V5) interspersed with more 
conserved domains (Clapham and McKnight, 2002).  The gp41 protein is relatively 
conserved in structure (Clapham and McKnight, 2002).  It is thought that the variable 
loops in gp120 may help replicating virus escape antibody-mediated neutralization 
(Clapham and McKnight, 2002). 
The CD4 Receptor 
 
 The HIV-1 virus utilizes the CD4 receptor as the major receptor.  CD4 is most 
commonly found on T-helper/inducer subset of lymphocytes, certain lineages of 
macrophages, and in some types of dendritic cells (Knipe and Howley, 2001).  Thus, 
CD4 expression is a major determinant of HIV cell tropism.  CD4 functions primarily as 
an accessory receptor in the cellular immune response to increase the attraction between 
helper T cells and MHC class II+ antigen presenting cells (Clapham and McKnight, 
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2002).  CD4 binds gp120 causing rearrangement of the gp120 core (Myszka et al, 2000).  
This conformational change in gp120 causes movement of the variable loops of the 
protein which exposes a binding site for a co-receptor, usually CCR5 or CXCR4 
(Clapham and McKnight, 2002).  CCR5 and CXCR4 are a part of the seven 
transmembrane (7TM) chemokine receptor family (Clapham and McKnight, 2002).  
There are also other types of co-receptors in the same family as CCR5 and CXCR4 but 
they are used less extensively than CCR5 or CXCR4 (Clapham and McKnight, 2002). 
HIV Co-Receptors and Fusion 
 
 The binding of HIV to the co-receptor is thought to be the trigger for membrane 
fusion, see Figure 4 (Doms and Moore, 2000).  The HIV-1 Env mediated fusion model 
that is most widely accepted proposes the extension a coiled-coil in gp41 that protrudes 
the fusion peptide which embeds in the cell membrane (Doms and Moore, 2000).  The 
protein gp41 then folds back on itself to form a six helix bundle that brings viral and call 
membranes in close proximity to each other (Doms and Moore, 2004).  The exact 
mechanisms that confer fusion of viral and cell membranes following these events are 
less clear.  The observed transmembrane structures in HIV-1 for fusion are consistent 
with other unrelated enveloped viruses (Clapham and McKnight, 2002).  Figure 4 below 
shows the viral entry step of HIV and the interactions of gp120 and gp41. 
 
Figure 4: Model of HIV-1 Env Membrane Fusion (Doms and Moore, 2000). 
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The interactions between gp120 and CD4 co-receptors determine HIV’s tropism 
(i.e. which host cells it enters).  The sites on gp120 that dictate tropism and co-receptor 
binding include the Variable loops V1/V2, V3, and also a conserved region of β-strands 
(Clapham and McKnight, 2002).  Variations in the variable loops are thought to enable 
HIV to interact differently with co-receptors (Clapham and McKnight, 2002).  This 
variability may help the virus escape immune response and/or expand its tropism toward 
other co-receptor sites (Clapham and McKnight, 2002).  Figure 5 shows a ribbon diagram 
of gp120 illustrating the bridging sheet located between the V1/V2 and V3 loop.  
Variation in structure in the V3 loop switches co-receptor use from CCR5 to CXCR4 
(Clapham and McKnight, 2002). 
Chemokine receptors are rod like structures in the membrane that have a center 
pore surrounded by 7 transmembrane regions (Clapham and McKnight, 2002).   
   
Figure 5: Structure of gp120 After CD4 Is 
Bound. The bridging sheet and sites on the 
V3 loop contact the co-receptor.  Arrows 
show discontinuous regions that bind CD4 
(Kwong et al, 1998).         
 
 
 
 
 
Chemokine receptors have four domains exposed from the surface of the cell; the 
domains are the N-terminus and 3 extracellular loops E1, E2, and E3 (Clapham and 
McKnight, 2002).  The N-terminus of CCR5 is important for HIV entry (Hill et al, 1998).  
 14
Mutagenesis to this domain of the CCR5 receptor has shown to eliminate entry of HIV-1 
R5 type viruses (Hill et al, 1998). 
 Individuals who are homozygous for a genetic defect that eliminates functional 
CCR5 are strongly protected from HIV-1 infection (Moore et al, 2004).  Individuals who 
are heterozygous for this genetic defect have slow disease progression (Moore et al, 
2004).  Individuals who lack the CCR5 receptor can be infected with HIV-1 strains that 
utilize the CXCR4 but this occurs only rarely (Moore et al, 2004).  The importance of co-
receptors and co-receptor usage for HIV-1 replication and cell tropism is very significant.  
The HIV-1 virus can use several different cellular receptors from the chemokine family 
as co-receptors for infection in vitro.  However, there is little evidence to support use of 
co-receptors other than the major receptors CCR5 and CXCR4.  Figure 6 shows a model 
of HIV-1 variants and the different types of co-receptors the virus utilizes.     
 
Figure 6: Currently Accepted Model for HIV-1 Co-Receptor Usage.  R5 tropic 
strains are specific for the CCR5 receptor on memory T-cells and can also infect 
primary macrophages.  X4 tropic viruses or viruses utilizing the CXCR4 receptor 
can infect CD4+ Naïve T-cell lines as well as certain macrophages.  R5X4 strains, 
also known as dual tropic can infect using either the CCR5 or CXCR4 receptors 
(Figure updated from Berger et al, 1999). 
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 Theory of Expanded Tropism of HIV-1 
 
 HIV, like other retroviruses, exhibits genetic diversity and variation through 
nucleotide substitutions, deletions, insertions, and homologous and non-homologous 
recombination (Coffin, et al, 1997).  HIV significantly exhibits genetic diversity where 
the virus changes over time within an infected individual (Kitrinos et al, 2003).  The 
factors that contribute to HIV’s variability include the high rate of replication, an error 
prone revere transcriptase (HIV’s DNA polymerase), and efficient recombination 
(Kitrinos et al, 2003).  The ability of HIV to change allows it to escape immune response 
and also to expand its tropism to different cell types.  Genetic variability is not equal 
along the HIV genome (Kitrinos et al, 2003).  The env gene exhibits the most genetic 
variation (Kitrinos et al, 2003).  The env gene encodes two proteins gp120 and gp41.  
Gp120 is most variable with 5 variable loops.  The V3 loop predominantly defines the 
virus’s tropism as R5 or X4 (Kitrinos et al, 2003), although other env regions (e.g. V1V2) 
also contribute (Hoffman et al, 2002).  R5 viruses are usually present at all stages of 
infection.  However X4 and/or X4R5 usually emerge in late stages of disease progression 
marked by the decline of the immune responses (Labrosse et al, 2001).  Most HIV+ 
individuals are infected initially with an R5 virus.  The R5 virus can lead an individual to 
progress to AIDS in the absence of X4 or R5X4 viruses.  It is unclear whether the R5 
tropism broadens during the course of infection without utilizing another type of receptor.  
It has been observed that in 50% of people infected with HIV the viral tropism switches 
to X4 and/or R5X4 late in disease.  This switch has been rarer in clade C infections in 
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Africa.  The broader tropism of this late stage switch allows HIV to colonize new T-cell 
populations.   
HIV Infection in Brain 
 HIV predominantly infects microglia and perivascular macrophages in the brain.  
In the perivascular region of the brain, cells come in contact with infected cells in the 
blood (González-Scarano et al, 2005).  The brain macrophages and the microglia cells are 
the brain’s resident immune cells that respond to all types of stimuli (González-Scarano 
et al, 2005).  The cells have similar receptors to other phagocytic cells in the blood due to 
their derivation from the bone marrow in development (González-Scarano et al, 2005). 
Patient JR-CSF Strain of HIV 
 
 The JR-CSF strain of HIV was reported in 1987 in Science by Yoshio Koyanagi 
et al.  They studied virus from brain tissue and cerebrospinal fluid from several HIV+ 
individuals.  All of the patients they studied had AIDS encephalopathy (Koyanagi et al, 
1987).  The patient J.R. died with Kaposi’s sarcoma and severe AIDS encephalopathy 
(Koyanagi et al, 1987).  The brain of the patient exhibited many giant cell syncytia as 
seen from frontal lobe autopsy (Koyanagi et al, 1987).  Analysis of the patient samples 
indicated there were two genotypically different but related strains present (Koyanagi et 
al, 1987).  Thus JRFL from the brain was shown to be macrophage tropic (M-tropic), 
while JR-CSF was not, even though both strains use CCR5 (Koyanagi et al, 1987).   
JR-CSF and Expanded Tropism 
 The JR-CSF strain was studied by Boyd et al who isolated a variant virus that 
could replicate in CD4+ T-cell lines (Boyd et al, 1993).  Studies have shown that changes 
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in the V3 loop of the gp120 env protein can determine tropism (Hoffman et al, 2002), and 
a single amino acid substitution in V3 is sometimes sufficient to change the tropism of 
HIV to either X4 or R5 (Hoffman et al, 2002).  In the case of JR-CSF Boyd et al reported 
that the capacity of JR-CSF to replicate in CD4+ T-cell lines was due to a single base 
substitution in the V1 loop (Boyd et al, 1993).  Subsequently, Dejucq et al showed that 
the JR-CSF variant still used CCR5 and had not switched to using CXCR4 or other 
potential co-receptors (Dejucq et al, 1999).  Thus the T-cell line adopted variant of JR-
CSF, may provide information on how R5 viruses expand tropism in vivo without co-
receptor switch.  
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PROJECT PURPOSE 
 It has been reported that single base substitutions in the V3 and V1/V2 loops of 
gp120 can affect the tropism of HIV-1.  The strain JR-CSF of HIV-1 can infect primary 
cells but not CD4+ T-cell lines in vitro.  Boyd et al in 1993 published that the JR-CSF C3 
variant could infect the MOLT4 T-cell line that had low levels of CCR5.  The infection 
of the MOLT4 cells was said to be the result of a single amino acid substitution in the V1 
loop of gp120.  However the methodology required amplification of mutagenized virus in 
culture, which could have introduced of further mutations.  The MQP project first aimed 
to confirm these results utilizing a pseudotype virus that utilized a JR-CSF envelope with 
the specific V1 amino acid substitution.  The project also explored JR-CSF clones created 
from virus that was passaged 4 times through PBMCs.  The importance of this research is 
to explore the observation of HIV-1’s ability to switch tropism in late stages of infection.  
The function of the variable loops is not completely understood but observations show 
they determine the co-receptor usage.  These variable loops could be a target of therapy 
to prevent entry of the virus into host cells. 
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MATERIALS AND METHODS 
Construction of Variant Clones 
Construction of JR-CSF Clone with Single Point Mutation 
 The creation of the JR-CSF clone with a single mutation utilized several cloning 
steps.  The envelope expression vector (pSVIII) carrying the JR-CSF envelope was used 
to create the mutation.  Mutagenesis of JR-CSF pSVIII env with a Guanine to Alanine 
base substitution involved a PCR procedure.  Round 1 with tubes 1 and 2 used pairs of 
primers.  Tube 1 used C3 alpha (5’- AAA ATT AAC CCC ACT CTG TGT TAC -3’) and 
C3 kappa (5’- CAT CAT TCC CTC ACT ATT ACT AGT -3’) and tube 2 used primers 
C3 beta (5’- ACT AGT AAT AGT GAG GGA ATG ATG -3’) and C3 lambda (5’- ATT 
ACA ATT TCT GGA TCC CCT CCT -3’).  Each tube contained a total volume of 50 µl 
that contained: 2 µl of 100 µM dNTPs, 4 µl of PCR Buffer (Clontech), 0.5 µl of HiFi Taq 
Polymerase (Clontech), and 41 µl of PCR H2O, 1 µl of Sense Primer (C3 alpha or C3 
beta), 1 µl Anti-sense Primer (C3 kappa or C3 lambda) and 0.5 µl of JR-CSF pSVIII env 
[SalI].  The PCR reaction ran for 25 cycles of 94°C for 1 minute, 48°C for 1 minute, and 
72°C for 5 minutes.  The tubes were stored at 4°C.   
Round 2 of mutagenesis had a total volume of 50 µl and consisted of: 1 µl of C3 
alpha, 1 µl of C3 lambda, 2 µl of 100 µM dNTPs, 4 µl of PCR Buffer (Clontech), 1 µl of 
Tube 1 from round 1, 1 µl of Tube 2 from round 1, 0.5 µl of HiFi Taq enzyme (Clontech), 
39.5 µl of PCR H2O.  The PCR reaction ran for 25 cycles at 94°C for 1 minute, 48°C for 
1 min, and 72°C for 2 minutes.  The PCR reaction was stored at 4°C. 
 20
 The PCR reaction was then purified and cloned using an Invitrogen® PCR XL-
TOPO kit.  The colonies (23) were PCR screened using Qiagen Taq polymerase and the 
C3 alpha and C3 lambda primers to detect inserts.  The Kanr positively screened colonies 
were then grown in 3 mL of liquid LB + Km.  Plasmid DNA from the colonies was mini-
prepped using the Qiagen Mini-prep kit. 
 Plasmid DNA containing the mutated PCR product was digested using BsmI 
(NEB) and BamHI (NEB) in a dual digest and cloned into a pGEM construct that 
contained a SalI fragment from the pSVIII env JR-CSF.  Figure 7 shows a diagram 
illustrating the construction of the clone.  Restriction digests were carried out at 37°C 
using NEB Buffer.  The plasmid containing the vector was also treated with antartic 
phosphatase to prevent self-ligation.  PCR screening, test digestion and sequencing 
verified that the fragment was successfully cloned. 
 The pGEM construct now contained the single mutation in a pSVIII envelope SalI 
fragment.  The construct was digested using SalI (NEB) and ligated back into pSVIII JR-
CSF (Figure 7).  The final pSVIII JR-CSF with 1 point mutation (G to A) was verified by 
sequencing, test digests, and PCR.  All clones had glycerol stocks prepared and were 
stored at -80°C.  
 21
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Cloning Strategy Used To Construct Single Amino Acid Substituted 
pSVIII JR-CSF envelope.   
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Construction of JR-CSF RT Fragment Clones 
 The JR-CSF RT clones were made from viral RNA reverse transcribed from JR-
CSF passaged 4 times through PBMCs.  The Invitrogen kit SuperScript First-Strand 
Synthesis System for RT-PCR was used.  The primer used was envN (5’- CTG CCA 
ATC AGG GAA GTA GCC TTG TGT -3’).  After first-strand synthesis, amplification of 
the cDNA (PCR forward) was performed using the Invitrogen kit.  The only exception to 
the protocol was that Roche Expand HiFidelity Taq was used.  Primers envA (5’- GGC 
TTA GGC ATC TCC TAT GGC AGG AAG AA -3’) and envN were used.  In round two 
of RT-PCR envB (5’- AGA AAG AGC AGA AGA CAG TGG CAA TGA -3’) and 
envM (5’- TAG CCC TTC CAG TCC CCC CTT TTC TTT TA -3’) primers were used.  
An EtBr 0.8% agarose gel was run to verify positive bands.  Six samples were selected to 
be purified using a crystal violet gel and the Invitrogen® PCR XL-TOPO kit for cloning.  
After the fragment was inserted in the TOPO vector a PCR screen was done to verify the 
transformation and identify clones that carried a PCRed fragment as an insert.  The 
positive colonies were grown in 3 mL of LB + Km and then mini-prepped using the 
Qiagen Mini-prep Kit.  The fragments were then cut out of the TOPO vector utilizing a 
KpnI (NEB) restriction site.  The pSVIII JR-CSF was also digested with KpnI (NEB) and 
Antartic Phosphatase to prepare for ligating to the RT fragment.  The pSVIII JR-CSF 
[KpnI] was ligated with the RT fragment from the TOPO vector after being cut with 
KpnI (see Figure 8).  The ligation and transformation was verified by PCR screen and test 
digestion to check orientation of fragments.  All clones (7) had glycerol stocks prepared 
and stored at -80°C.  The Qiagen Mini-prep kit was used to prepare the DNA from the 7 
clones. 
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 Figure 8: Map Of The pSVIII Expression Vector.  The KpnI (orange) restriction 
sites were utilized to clone the RT fragments into pSVIII. 
Testing Variant Clones using Cell based Assays 
Transfection of 293T cells 
 Transfections of the clone DNA and an HIV backbone were done using the 
Profection® Mammalian Transfection System from Promega.  The HIV backbone is 
derived from the NL4.3 standard of HIV-1 and encodes all HIV-1 genes except envelope.  
One day before transfection 293T cells were plated in a 6 well plate at 1x105 cells/mL, 2 
mL in each well.  Dulbecco’s modified Eagle Medium (DMEM) + 4% Fetal Bovine 
Serum (FBS) + Gentamicin media was used.  The cells were incubated at 37°C in 5% 
CO2 cabinets overnight.  On the day of transfection the cells had their media changed at 
least 3 hours prior to transfection.  The transfection was calculated by determining the 
concentration of the Env clone’s DNA and the L4-1-1 Backbone’s DNA.  The 
concentration used for each of the DNAs was 1.25 µg/µl.  The preparation of each clone 
to be transfected was done by using two 14 mL snap cap tubes (poly-propylene).  Tube A 
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had the clone Env DNA, backbone DNA, 2M CaCl2 (10.34 µl), and Nuclease-free H2O to 
bring the final volume to 83.40 µl.  Tube B had 83.40 µl of 2X HEPES buffered saline.  
Tube A was added to Tube B dropwise while vortexing.  The mixed tubes were incubated 
at room temperature for 30 minutes.  After 30 minutes the transfection (166.8 µl) was 
added to a well of 293T cells.  The transfection was added dropwise while slowly 
swirling to distribute DNA evenly. 
 
 
Figure 9: HIV-1 Backbone Derived from NL4.3.  The backbone has a premature 
stop codon in the env gene. 
HeLa Cell Fusion Assay 
 The HeLa cell fusion assay was done using 293T cells that had been transfected 
with pSVIII env and backbone DNA and were therefore expressing envelope on the cell 
surface.  Control envelopes typically used were pSVIII: P20 B59, P20 LN8, P6 LN40, 
P353 B27 and SF162.  The wild-type JR-CSF was also used as a control.  On the same 
day that the 293T cells were transfected, HeLa cells (8 lines) were plated in 48-well trays.  
The cells were plated at 8 x104 cells/mL with 500 µl per well.  The medium used was 
DMEM + 4% FBS + Gentamicin.  The cells were incubated overnight so they could 
attach to the well.  The cell types used were a RC line that has low CD4 presentation, and 
a JC line that has a high CD4 presentation.  The lines each had varying amounts of CCR5 
and are shown in Table 2. 
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Level of CCR5 High CD4 Low CD4 
High JC53 RC49 
Medium JC37 RC23 
Low JC10 RC33 
None HIJ HIR 
     
Table 2: Chart of Different HeLa Cell Types and Their Receptor Concentration the 
CD4 and CCR5 receptors. 
 
The 293T cells were added to each of the wells usually in different concentrations.  The 
cells were plated at 2 x105 cells/mL in 50 µl and 100 µl amounts.  After addition of the 
HeLa cells the plates were incubated for 4 hours.  After 4 hours the plates were fixed and 
stained for syncytia.  The plates had all the media aspirated off and then were washed 
twice with 1X Phosphate Buffer Solution (PBS).  Addition of the syncytia stain (1% 
methylene blue, 0.28% basic fuchsin in methanol) was added and allowed to sit for 10 
minutes.  After 10 minutes had passed the stain was removed and the wells were rinsed 
using dH2O.  The wells then had some 1X PBS/0.05% Azide added as a preservative to 
prevent bacterial growth.  The wells were scored and photographed using an inverted 
light microscope. 
MOLT 4 Clone 8 Fusion Assay 
 MOLT 4 Clone 8 (MOLT4/8) cells are a suspension cell line that was grown in 
RPMI medium + 10% FBS + Gentamicin.  The cell line was derived from a young adult 
with acute lymphoblastic leukemia.  The cells express CD4 and CXCR4 in equal 
concentrations and a very low amount of CCR5.  293T cells were transfected the day 
before infection.  The cells were then were added to 48 well plate wells at 5 x 104 
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cells/mL at 400 µl per well.  The MOLT4/8 cells were added to each well at 100 µl in 3 
different concentrations 5 x 105/mL, 2.5 x 105/mL, and 1.25 x 105/mL.  The cells were 
checked after 24 and 48 hours.  Cells were scored for syncytia formation and photographs 
were taken. 
Production of Pseudotype Virus Stocks 
 Transfection of 293T was performed as described on page 24.  After 24 hours of 
incubation media was changed.  After another 24 hours (48 hours after transfection) the 
media was pipetted off each well and added to 15 mL centrifuge tubes.  The tubes were 
centrifuged for 10 minutes at 1,200 rpm to remove cell debris.  The supernatant from 
each vial was added to cryrovials in 0.5 mL amounts.  The vials were then "snap" frozen 
in liquid nitrogen.  After at least one hour had passed the vials were stored in a -152 °C 
freezer.   
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RESULTS 
 The main goal of the project was to further examine the determinants of the HIV-
1 envelope that broaden tropism of R5 viruses without a co-receptor.  The project first 
investigated a single amino acid change in the V1 loop reported to broaden tropism.  The 
project further investigates changes observed in the variant JR-CSF after a short passage.  
The project aims are to correlate the phenotypic differences of the variant clones when 
compared to wild-type.  Genotypic differences are identified as possible causes of the 
phenotypic differences between variant clones. 
Construction of Variant Clones 
 There were two different types env of clones constructed.  The first clone was the 
JR-CSF with a single amino acid substitution.  The second type of clones constructed was 
reverse-transcribed from JR-CSF virus passage 4 times in PBMCs. 
JR-CSF Variant with Point Mutation 
 JR-CSF S141N was reported by Boyd et al in 1993.  The same mutation was put 
into the pSVIII envelope encoding the JR-CSF envelope using PCR mutagenesis.  The 
protocol that Boyd et al used to produce JR-CSF S141N involved amplification of the 
mutant virus in PBMCs.  Such conditions may allow the introduction of additional 
mutations.  The method I used to verify Boyd’s mutation using a system that involves 
only 1 round of virus replication does not provide opportunity for further culture 
introduced mutations in envelope.  Sequence analyses confirmed the Serine to 
Asparagine substitution (S141N).  This change does not introduce or eliminate an N-
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linked glycosylation site.  Figure 10 shows pictures of gels from the test digestions that 
were done to check orientation of the ligated fragment. 
 
A B 
 
Figure 10: Test Restriction Digest of JR-CSF point mutated clones.  XhoI (NEB) 
and MfeI (NEB) were used to cut the clones.  Gel A has the following in its lanes:  1) 
10 kb DNA Marker, 2-5) clones 2-6, 6) JR-CSF wild-type.  Gel B has the following: 
1) 10 kb DNA Marker, 2-10) clones 7-15. 
 
 Amino Acid sequence of the V1V2 loop of env gene where the one point amino 
acid substitution was introduced is seen in  
Figure 11.  The mutation takes place at position 141 and is a Serine to Asparagine switch. 
 
 
 
Figure 11: Amino Acid Sequence of JR-CSF and the JR-CSF S141N clone.  The 
location of the substitution is at amino acid 141 where a serine (blue) residue is 
substituted with an asparagine residue (red). 
 
JR-CSF Variants from Passage through PBMCs 
 JR-CSF viral RNA was obtained from JR-CSF virus that had been passaged 4 
times through PBMCs.  The RNA was reverse transcribed and the env fragment was 
obtained.  The env fragment was purified and digested using the KpnI restriction site.  
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The KpnI fragment of the JR-CSF P4 was ligated into pSVIII JR-CSF ∆KpnI expression 
vector.  After transformation the clones were screened by PCR.  Positives clones had an 
XhoI restriction digest performed to check the orientation of the fragment in pSVIII JR-
CSF ∆KpnI.  Figure 12 shows a gel run of the restriction digest with XhoI.  The envelope 
pSVIII JR-CSF was used as a positive control.  
 
Figure 12: Test Digest to Check Orientation of Inserts Using XhoI Restriction Site 
with JR-CSF P4 pSVIII Clones.  Lane are as followed: 1) 10 kb DNA marker, 2) 
positive control (pSVIII JR-CSF), 3-10) positively PCR screened clones.  Lane 9 is a 
clone that has the fragment in the wrong way. 
Cell Based Assays 
HeLa Cell Fusion Assays — JR-CSF Single Amino Acid Substitution Clone 
 
 The pSVIII env carrying JR-CSF envelope clones with the correct single amino 
acid substitution at residue 141 (JR-CSF S141N) were tested for functionality on several 
cell lines.  Seven clones were selected that were positive for the single point substitution 
and were transfected into 293T cells.  HeLa cells were co-cultivated with the 293T cells.  
After 24 hours the cells were fixed and stained and observed for fusion (data not shown).  
Two of the clones (3 and 8) were selected for further fusion assays. 
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 The clones were transfected into 293T cells along with a panel of control 
envelopes (Table 3).  The 293T cells were incubated overnight and then co-cultivated on 
8x104 HeLa Cells.  The HeLa cell lines used were RC (Low CD4) and JC (High CD4) 
with varying concentrations of CCR5 (see Table 2, page 26).   
 
Control Envelope Macrophage Infection Infection via Low CD4/Low CCR5 
P20 B59 + + 
P20 LN8 - - 
P353 B27 + + 
P6 LN40 - - 
SF162 + + 
JR-CSF wild-type - +/- 
 
Table 3: Controls Used In HeLa Cell Fusion Assay.  HeLa cell assays were 
performed using pSVIII envelope controls.  Positive (+) envelopes will cause the cells 
to fuse and can infect. 
 
The extent of syncytium formation was scored by eye (Table 4).  There was no 
significant difference between JR-CSF and the clones.  The scores were given on a scale 
that was based on the P20 B59 envelope that is able to exploit low CD4 and CCR5 for 
infection and on P20 LN8, an envelope cloned from the same patient as B59, but it 
requires high amounts of CD4 for fusion.   
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Virus RC33 RC23 RC49 HIR JC10 JC37 JC53 HIJ
P20 B59 + ++++ ++++ - - ++++ ++++ -
P20 LN8 - - + - ++ ++++ ++++ -
P6 LN40 - - - - + +++ ++++ -
P353 B27 - +++ ++++ - + ++++ ++++ -
JR-CSF - - ++ - ++ +++ ++++ -
JR-CSF S141N 3 - - ++ - ++ +++ ++++ -
JR-CSF S141N 8 - - ++ - ++ +++ ++++ -
 
Table 4: Scores of the HeLa Cell Fusion of S141N Clones.  The P20 B59 virus is the 
positive control.  Cell lines HIR and HIJ are negative controls.  The fusion assay was 
fixed and stained 4 hours post co-cultivation. 
 
 
 
Pictures of the HeLa cells were taken at 200X magnification.  Syncytia formation is due 
to cell: cell fusion events that occur between env+ and receptor+ cells.  Figure 13 shows 
no significant difference when comparing JR-CSF wild-type versus the S141N clone.  In 
this assay, the P6 LN40 envelope that only fuses on high CD4 cell lines and was used as 
a control. 
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Figure 13:  HeLa Cell Fusion Assay Panel.  P20 B59 (positive control), P6 LN40, JR-
CSF wild-type, and JR-CSF S141N clone 8.  The cell lines photographed are: RC23 
(Low CD4, Med CCR5), RC49 (Low CD4, High CCR5), JC53 (High CD4, High 
CCR5).    
 
HeLa Cell Fusion Assays — JR-CSF Passage 4 RT Clones 
 Seven JR-CSF clones that were reverse transcribed from viral RNA after four 
passages were tested in similar fashion to that of the JR-CSF S141N clones.  The clones 
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were tested for their ability to fuse on various HeLa cell types.  The clones were scored 
just as the JR-CSF S141N clones.  The fusion assay was performed with two different 
concentration of 293T cells applied to each well, 50 and 100 µl.   
Table 5 shows the scores from the fusion assay.  The broad tropic control envelopes; and 
P353 B27 fused RC23 as expected.  Some of the clones were non-functional (7A1-4 and 
7B1-2).  At least two clones (5A4-2 and 7B4-1) conferred higher amounts of fusion on 
RC49 when compared to the wild-type JR-CSF.   
 
 
 
 
 
 
 
 
 
 
 
 
Table 5: HeLa Fusion Score for the JR-CSF Passage 4 RT Clones.  The scoring is 
based on the amounts of syncytia formation observed.  The concentration is the 
amount of 293T cells co-cultivated with the HeLa cells.  The wells were scored four 
hours post co-cultivation. 
 
The differences observed between the clones and JR-CSF are shown in Figure 14.  Many 
more syncytia were observed in RC49 co-cultivation for envelopes 5B4-2 and 7B4-1.   
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RC23 RC49 JC53 
 
 
 
 
 
 
 
 
 
 
      
   
 
Figure 14: HeLa Cell Fusion Assay of JR-CSF P4 RT Clones.  Pictures were taken 4 
hours post co-cultivation.  The magnification was at 100X. 
 
MOLT4 Clone 8 Cell Fusion Assay 
 The MOLT4 Clone 8 (MOLT4/8) cell line is derived from a young adult with 
acute lymphoblastic leukemia.  These cells express the CD4 and CXCR4 in equal 
concentrations on the cell surface, but express CCR5 in only trace amounts on the cell 
surface.  Molt4/8 cells cultures also contain a low level of small background syncytia, 
which has to be taken into account in syncytial assays.  The assay was performed by co-
cultivating transfected 293T cells along with MOLT4/8 cells.  The MOLT4/8 cells are 
plated in three concentrations of cells: 5 x 105/mL, 2.5 x 105/mL, and 1.25 x 105/mL.  
Table 6 shows the scores seen 1 day after the cells were co-cultivated.  The JR-CSF wild-
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type and JR-CSF S141N had almost identical amounts of fusion observed which 
appeared to be background.  The two JR-CSF RT P4 clones have a significant amount of 
fusion observed when comparing to the JR-CSF wild-type.  This can be seen in Figure 15 
where there are larger and more syncytia are present.  Syncytia are seen by large circular 
formations illustrated by arrows. 
 
 
 
 
 
 
 
Virus P20 B59 JR-CSF P4 JR-CSF P4 JR-CSF JR-CSFP353 B27 Neg Ctrl
 
Table 6:  Scores of MOLT4 Clone 8 Fusion Assay.  Cells were scored 1 day after co-
cultivation of 293T cells and the MOLT4/8 cells.  The assay was performed in 3 
different concentrations.  P20 B59 is the positive control and JR-CSF is the wild-
type control. 
 
 
Figure 15:  Picture of MOLT4 Clone 8 Fusion Assay.  Pictures taken at 100X 
magnification one day after co-cultivation with 293T cells.  Negative control had no 
293T cells added; P20 B59 was the positive control.  The arrows indicate a syncytia 
formation. 
JR-CSF P4 7B4-1 JR-CSF P4 5A4-2 
JR-CSF S141N JR-CSF (WT) P20 B59 
Negative Ctrl 
S141N 5A4-2 7B4-1 
5 x105 +++++ +++ + + ++++ +++++ +
2.5 x 105 +++++ +++ + + +++ ++++ +
1.25 x 105 +++++ ++ + + +++ ++++ +
293T Cell Conc. 
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Sequence Analysis— JR-CSF RT Clones 
 Sequence analysis of the JR-CSF clones was performed on the V1/V2 loop and 
V3 loop using specific env primers.  The primers used were specific for V1/V2 and V3/a 
portion up stream that includes the CD4 binding site.  Figure 16 shows the alignment of 
the clones with JR-CSF wild-type.  There are two differences observed, one in each 
clone.  Clone 5A4-2 has a 1 pt substitution in the CD4 binding site of gp120 where an 
aspartic acid residue is substituted for an asparagine residue.  Figure 17 show the sites a 
CD4 that bind on gp120, the yellow arrow indicates the location to where the point 
mutation is observed.  Clone 7B4-1 has a 1 point substitution in the V2 loop of gp120 
where an aspartic acid residue is substituted with an asparagine residue. 
 
Figure 16: Sequence Analysis of the V1V2 Loop, CD4 Binding Site, and V3 Loop of 
gp120.  Analysis performed on two of the RT JR-CSF P4 and aligned with JR-CSF 
wild-type.  Conserved amino acids are in blue, red amino acids are substitutions. 
 
 
 
Figure 17: Structure Of gp120 Protein.  The arrows 
indicate the points to which CD4 binds.  The yellow 
arrow indicates the location to where clone 5A4-2 has 
a substituted Asparagine residue. 
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DISCUSSION 
 HIV-1 predominately uses CD4 and a chemokine receptor to gain entry into host 
cells.  The class of HIV-1 that is most commonly transmitted uses the chemokine 
receptor CCR5 (R5).  It is observed in 50% of AIDS patients in late stage of disease that 
the virus switched to use CXCR4 as a co-receptor.  CXCR4 using viruses have widely 
expressed an expanded tropism among T-cell populations.  Patients that lack X4-using 
viruses also develop AIDS and may evolve R5 viruses with a broader cell tropism.  Broad 
tropic R5 viruses were discovered in the brain of AIDS patients.  Broader tropism was 
conferred by the capacity to infect cells via low CD4 and low CCR5 levels.  The project 
aimed to further elucidate the envelope determinants of R5-using HIV-1 that broaden in 
tropism and may increase cell death of T-cells late in disease. 
Most HIV research is performed on virus isolates.  The isolation of HIV strains 
involves culture in the absence of immune response (in vitro).  This allows for the 
potential to select for variants with different properties than would be seen in an immune 
responsive environment (in vivo).  A possibility that is theorized about the virus and its 
response to immune environments is that the variables loops (e.g. V1V2) sit over the 
CD4 co-receptor binding site to protect it from neutralizing antibodies.  Culture in vitro 
may allow more exposure of env proteins to receptors and increase its interaction.  Thus, 
variants may evolve that can infect cells with lower receptor levels and allow the tropism 
to broaden.  The environment that brain is apart of is one that is immuneprivileged and 
coincides with the type of environment the virus is exposed with in vitro since there is no 
presence of neutralizing antibodies.   
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 The first variant the project looks at is the JR-CSF mutant that Boyd et al reported 
in 1993 as changing tropism.  The mutant of JR-CSF (S141N) had a single amino acid 
substitution at residue 141 of gp120’s V1 loop from Ser-Asn.  The observation of the JR-
CSF S141N was that it expressed a greater amount of infection on MOLT4/8 cells.  
Boyd’s results had a clear and significant difference between the mutant and JR-CSF 
wild-type.  The project results show very little or no difference in cell fusion between the 
wild-type and the JR-CSF S141N mutant.  Dejucq et al reported in 1999 that CCR5 
inhibitors sensitively blocked infection by JR-CSF S141N.  This confirmed that the 
mutant still requires the CCR5 receptor for infection.  The CCR5 receptor is present in 
trace amounts on MOLT4/8 cells.  As discussed above, Boyd et al results could possibly 
be explained by the method to how the virus was amplified.  The virus was passaged 
through PBMCs before the infectivity assays which could have introduced other 
mutations.  The project demonstrates through several cell fusion assays involving HeLa 
and MOLT4 cell lines expressing known concentrations of the CCR5 receptor that there 
is no significant difference between the JR-CSF wild-type and JR-CSF S141N.  
Infectivity assays that will be needed to confirm results seen by the cell: cell fusion 
assays have been initiated. 
 In contrast to S141N mutant, two variant envelopes cloned from JR-CSF passaged 
just 4 times through PBMCs showed distinct differences in capacity to induce HeLa and 
MOLT4/8 fusion.  The differences observed in the phenotype when compared to S141N 
and JR-CSF wild-type could be examples of the virus having a broadening of tropism 
toward either low levels of CCR5 or utilizing the CXCR4 receptor that is present in 
MOLT4/8 T-cells.  Sequence analysis of the two variant clones identified single point 
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mutations in both clones.  A mutation in the 5A4-2 clone is located in the CD4 binding 
site, an Aspartic Acid – Asparagine residue substitution.  This mutation might show a 
stronger interaction with CD4 helping the virus utilize the low levels of CCR5.  The other 
mutation observed in the 7B4-1 clone is a change in the V2 loop where an Aspartic Acid 
residue is substituted for an Asparagine.  Further sequencing of the envelope genome is 
needed to determine if these substitutions are the only observed changes from a short 
passage of 4 times.  Further confirmatory studies of creating mutants with these observed 
substitutions should be performed to elucidate the broaden tropism. 
 The project exemplifies HIV-1’s ability to rapidly evolve an altered phenotype 
during in vitro and in vivo.  Here, I studied how limited genetic changes acquired in vitro 
can affect virus phenotype.  Phenotypic variations in R5-using viruses that alter tropism 
have implication for viral transmission and death of CD4+ cells in disease progression, as 
well as research on HIV-1 isolated by in vitro culture.          
    
 40
Bibliography 
 
Aiken C, Trono D  (1995)  Nef stimulates human immunodeficiency virus type 1 proviral  
DNA synthesis.  Journal of Virology 69: 5048- 5056. 
 
Berger EA, Murphy PM, Farber JM  (1999)  Chemokine receptors as HIV-1 coreceptors: 
 roles in viral entry, tropism, and disease.  Annual Review of Immunology 17: 657- 
 700. 
 
Boyd MT, Simpson GR, Cann AJ, Johnson MA, Weiss RA  (1993)  A Single amino acid  
 substitution in the V1 loop of human immunodeficiency virus type 1 gpl20 alters 
 cellular tropism.  Journal of Virology 67: 3649-3652. 
 
Bukrinsky M, Adzhubei A  (1999)  Viral protein R of HIV-1.  Reviews of Medical  
Virology 9: 39-49. 
 
Chowers MY, Spina CA, Kwoh TJ, Fitch NJ, Richman DD, Guatelli JC  (1994)  Optimal  
infectivity in vitro of human immunodeficiency virus type 1 requires an intact nef  
gene.  Journal of Virology 68: 2906-2914. 
 
Clapham PR, McKnight A (2002)  Cell surface receptors, virus entry and tropism of 
primate lentiviruses.  Journal of General Virology 83: 1809-1829. 
 
Coffin J, Hughs S, Varmus H (1997) Retroviruses.  Plainview, NY: Cold Spring Harbor  
Laboratory Press, 1997.  Accessed via NCBI Website:  
http://www.ncbi.nlm.nih.gov/books/. 
 
Cohen O, Kinter A, Fauci AS (1997)  Host factors in the pathogenesis of HIV disease.   
Immunological Reviews 159: 31-48. 
 
Dejucq N, Simmons G, Clapham PR  (1999)  Expanded tropism of primary human 
 immunodeficiency virus type 1 R5 strains to CD4+ T-cell lines determined by the 
 capacity to exploit low concentrations of CCR5.  Journal of Virology 73: 7842- 
 7847. 
 
Desrosiers RC, Letvin NL  (1987)  Animal models for acquired immunodeficiency  
syndrome. Reviews in Infectious Disorders 9: 438-446. 
 
Doms R, Moore J  (2000)  HIV-1 membrane fusion: targets of opportunity.  The Journal 
of Cell Biology 151: F9-F13. 
 
Fauci AS, Pantaleo G, Stanley S, Weissman D (1996) Immunopathogenic mechanisms of  
HIV Infection.  Annals of Internal Medicine 124: 654-663. 
Freed EO  (2002)  Mini review: Viral Late Domains.  Journal of Virology 76:  4679-  
 4687. 
 41
 
Hoffman NG, Seillier-Moiseiwitsch F, Ahn JH, Walker J, Swanstrom R  (2002) 
 Variability in the human immunodeficiency virus type 1 gp120 Env protein 
 linked to phenotype-associated changes in the V3 Loop.  Journal of Virology 76: 
 3852-3864. 
 
Gabuzda DH, Li H, Lawrence K, Vasir BS, Crawford K, Langhoff E  (1994)  Essential  
role of vif in establishing productive HIV-1 infection in peripheral blood T  
lymphocytes and monocyte/macrophages.  Journal of Acquired Immune 
Deficiency Syndromes 7: 908-915. 
 
González-Scarano F, Martín-García J  (2005)  The nueropathogenesis of AIDS.  Nature 
 Reviews Immunology 5: 69-81. 
 
Kitrinos KM, Hoffman NG, Nelson JAE, Swanstrom R  (2003)  Turnover of env  
 variable region 1 and 2 genotypes in subjects with late-stage human  
 immunodeficiency virus type 1 infection.  Journal of Virology 77: 6811- 6822. 
 
Knipe DM, Howley PM (2001) Fundamental Virology, 4th edition.  Philadelphia, PA:  
Lippincott Williams & Wilkins, 913-922. 
 
Koyanagi Y, Miles S, Mitsuyasu RT, Merrill JE, Vinters HV, Chen ISY  (1987)  Dual 
 infection of the central nervous system by AIDS viruses with distinct cellular 
 tropisms.  Science 236: 819-822. 
 
Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA  (1998)  
 Structure of an HIVgp120 envelope glycoprotein in complex with the CD4 
 receptor and a neutralizing human antibody.  Nature 393: 648-659. 
 
Labrosse B, Treboute C, Brelot A, Alizon M  (2001)  Cooperation of the V1/V2 and V3 
 domains of human immunodeficiency virus type 1 gp120 for interaction with the 
 CXCR4 receptor.  Journal of Virology 75: 5457-5464. 
 
Losman B, Bolmstedt A, Schonning K, Bjorndal A, Westin C, Fenyo EM, Olofsson S   
(2001)  Protection of neutralization epitopes in the V3 loop of oligometric human  
immunodeficiency virus type 1 glycoprotein 120 by N-linked oligosaccharides in  
the V1 region.  AIDS Research and Human Retroviruses 17: 1067-1076. 
 
Myszka DG, Sweet RW, Hensley P, Brigham-Burke M, Kwong PD, Hendrickson WA,  
Wyatt R, Sodroski J, Doyle ML (2000) Energetics of the HIV gp120-CD4 binding 
reaction.  Proceedings of National Academy of Sciences 97: 9026-31. 
 
Moore JP, Kitchen SG, Pugach P, Zack JA (2004) The CCR5 and CXCR4 coreceptors – 
 central to understanding the transmission and pathogenesis of human 
 immunodeficiency virus type 1 infection.  AIDS Research and Human 
 Retroviruses 20: 111-126. 
 42
 
Rhim H, Rice AP  (1994)  Exon2 of HIV-2 Tat contributes to transactivation of the HIV- 
2 LTR by increasing binding affinity to HIV-2 TAR RNA.  Nucleic Acid  
Research 22: 4405-4413. 
 
Rose KM, Marin, Kozak SL, Kabat D  (2004)  The viral infectivity factor (Vif) of HIV-1 
 unveiled.  TRENDS in Molecular Medicine 10: 291- 297. 
    
Wiley S (2001) Ph.D. Dissertation.  UMASS Medical School Program in Molecular  
Medicine. 
 
Willey RL, Maldarelli F, Martin MA, Strebel K (1992)  Human immunodeficiency virus 
type 1 Vpu protein induces rapid degradation of CD4.  Journal of Virology 66: 
7193-7200. 
 43
